Lilly's tirzepatide aces 2 more late-phase diabetes trials

Two more phase 3 clinical trials of Eli Lilly’s tirzepatide in Type 2 diabetics have met their primary endpoints. The studies, like a trial that read out late last year, linked the dual GIP/GLP-1 agonist to significant declines in blood sugar and body weight.